Advertisement

Reports of suicidality in clinical trials of montelukast

      Background

      In recent years, a number of drugs and drug classes have come under scrutiny by the US Food and Drug Administration regarding suicidality (including suicidal behavior and ideation).

      Objective

      We sought to perform 2 reviews (requested by the US Food and Drug Administration) of the number of events possibly related to suicidality reported in Merck clinical trials of montelukast.

      Methods

      Method 1 was a descriptive review of clinical adverse experiences (AEs) from 116 studies (double-blind and open-label, adult and pediatric, and single- and multiple-dose studies) completed as of March 2008. Summaries were constructed from investigator-reported AE terms possibly related to suicidality (completed suicide, suicide attempt, and suicidal ideation) or self-injurious behavior. Method 2 used a retrospective adjudication of investigator-reported AEs and other events listed in the study database described as possibly suicidality-related adverse events (PSRAEs) in a prespecified set of 41 double-blind, placebo-controlled trials completed as of April 2008.

      Results

      No completed suicides were reported in any study. For the descriptive review, 20,131 adults and children received montelukast, 9,287 received placebo, and 8,346 received active control; AEs possibly related to suicidality were rare and were similar between the montelukast and placebo or active-control groups. For the adjudicated review across 22,433 patients, there were 730 adjudicated events. In 9,929 patients taking montelukast, 1 PSRAE was identified (classified as suicidal ideation); none were identified in 7,780 and 4,724 patients taking placebo and active control, respectively.

      Conclusions

      Assessed by using 2 complementary methods, there were no reports of completed suicide, and reports of PSRAEs were rare in patients receiving montelukast and similar to those seen in control subjects.

      Key words

      Abbreviations used:

      AE (Adverse experience), C-CASA (Columbia Classification Algorithm of Suicide Assessment), FDA (US Food and Drug Administration), MRL (Merck Research Laboratories), PSRAE (Possibly suicidality-related adverse event), SCC (Suicide Classification Center)
      To read this article in full you will need to make a payment

      References

        • US Food and Drug Administration
        Early communication about an ongoing safety review of montelukast (SINGULAIR).
        (Available at) (Accessed August 10, 2009)
        • US Food and Drug Administration
        Update of safety review: follow-up to the March 27, 2008, communication about the ongoing safety review of montelukast (Singulair).
        (January 13, 2009. Available at) (Accessed August 10, 2009)
        • US Food and Drug Administration
        Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR).
        (June 12, 2009. Available at) (Accessed August 10, 2009)
        • Posner K.
        • Oquendo M.
        • Gould M.
        • Stanley B.
        • Davies M.
        Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.
        Am J Psychiatry. 2007; 164: 1035-1043
      1. Psychopharmacologic Drugs Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/cder04.html#PsychopharmacologicDrugs. Accessed August 10, 2009.

      2. US Food and Drug Advisory Committee FDA briefing document: Zimulti™ (rimonabant) tablets, 20 mg. Available at: http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm. Accessed August 10, 2008.

      3. Suicidal behavior and ideation and antiepileptic drugs. Available at: http://www.fda.gov/cder/drug/infopage/antiepileptics/default.htm. Accessed August 10, 2009.

        • Bisgaard H.
        • Skoner D.
        • Boza M.L.
        • Tozzi C.A.
        • Newcomb K.
        • Reiss T.F.
        • et al.
        Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions.
        Pediatr Pulmonol. 2009; 44: 568-579
        • Holbrook J.T.
        • Harik-Khan R.
        Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials.
        J Allergy Clin Immunol. 2008; 122: 828-829
        • Jick H.
        • Hagberg K.W.
        • Egger P.
        Rate of suicide in patients taking montelukast.
        Phamacotherapy. 2009; 29: 165-166
        • Kessler R.C.
        • Berglund P.
        • Borges G.
        • Nock M.
        • Wang P.S.
        Trends in suicide ideation, plans, gestures, and attempts in the United States, 1990-1992 to 2001-2003.
        JAMA. 2005; 293: 2487-2495
        • Nock M.K.
        • Borges G.
        • Bromet E.J.
        • Cha C.B.
        • Kessler R.C.
        • Lee S.
        Suicide and suicidal behavior.
        Epidemiol Rev. 2008; 30: 133-154
        • Centers for Disease Control and Prevention (CDC)
        Web-based Injury Statistics Query and Reporting System (WISQARS [online]) 2005.
        (National Center for Injury Prevention and Control, CDC (producer). Available at) (Accessed August 10, 2009)
        • Centers for Disease Control and Prevention (CDC)
        Suicide trend among youths and young adults aged 10-24 years—United States, 1990-2004.
        MMWR Morb Mortal Wkly Rep. 2007; 56: 905-908
        • Nock M.K.
        • Borges G.
        • Bromet E.J.
        • Alonso J.
        • Angermeyer M.
        • Beautrais A.
        • et al.
        Cross-national prevalence and risk factors for suicidal ideation, plans and attempts.
        Br J Psychiatry. 2008; 192: 98-105
        • Druss B.
        • Pincus H.
        Suicidal ideation and suicide attempts in general medical illnesses.
        Arch Intern Med. 2000; 160: 1522-1526
        • Goodwin R.D.
        • Eaton W.W.
        Asthma, suicidal ideation, and suicide attempts: findings from the Baltimore Epidemiologic Catchment Area follow-up.
        Am J Public Health. 2005; 95: 717-722
        • Goodwin R.D.
        • Marusic A.
        Asthma and suicide ideation among youth in the community.
        Crisis. 2004; 25: 99-102
        • Postolache T.T.
        • Stiller J.W.
        • Herell R.
        • Goldstein M.A.
        • Shreeram S.S.
        • Zebrak R.
        • et al.
        Tree pollen peaks are associated with increased nonviolent suicide in women.
        Mol Psychiatry. 2005; 10: 232-238
        • Guzman A.
        • Tonelli L.H.
        • Roberts D.
        • Stiller J.W.
        • Jackson M.A.
        • Sorian J.J.
        • et al.
        Mood-worsening with high-pollen-counts and seasonality: a preliminary report.
        J Affective Disorders. 2007; 101: 269-274
        • Yip P.S.F.
        • Yang K.C.T.
        • Qin P.
        Seasonality of suicides with and without psychiatric illness in Denmark.
        J Affect Disord. 2006; 96: 117-121
        • Postolache T.T.
        • Komarow H.
        • Tonelli L.H.
        Allergy: a risk factor for suicide?.
        Curr Treat Options Neurol. 2008; 10: 363-376
        • Manalai P.
        • Woo J.-M.
        • Postolache T.T.
        Suicidality and montelukast.
        Expert Opin Drug Saf. 2009; 8: 273-282
      4. SINGULAIR® (montelukast sodium) prescribing information.
        Merck & Co, Inc, Whitehouse Station (NJ)2009
      5. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics): suicidal ideation and behavior. US Food and Drug Administration Drug Safety Newsletter. Available at: www.fda.gov/downloads/Drugs/DrugSafety/DrugSafetyNewsletter/ucm107318.pdf. Accessed August 10, 2009.

        • Fang S.H.
        • Wei E.Q.
        • Zhou Y.
        • Wang M.L.
        • Zhang W.P.
        • Yu G.L.
        • et al.
        Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats.
        Neuroscience. 2006; 140: 969-979
        • Ciana P.
        • Fumagalli M.
        • Trincavelli M.L.
        • Verderio C.
        • Rosa P.
        • Lecca D.
        • et al.
        The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
        EMBO J. 2006; 25: 4615-4627
        • Peters-Golden M.
        • Henderson Jr., W.R.
        Leukotrienes.
        N Engl J Med. 2007; 357: 1841-1854
        • Uz T.
        • Dwivedi Y.
        • Pandey G.N.
        • Roberts R.C.
        • Conley R.R.
        • Manev R.
        • et al.
        5-Lipoxygenase in the prefrontal cortex of suicide victims.
        Open Neuropsychopharmacol J. 2008; 1: 1-5
        • Uz T.
        • Dimitrijevic N.
        • Tueting P.
        • Manev H.
        5-lipoxygenase (5LOX)-deficient mice express reduced anxiety-like behavior.
        Restor Neurol Neurosci. 2002; 20: 15-20
        • Uz T.
        • Dimitrijevic N.
        • Imbesi M.
        • Manev H.
        • Manev R.
        Effects of MK-866, a 5-liopoxygenase activating protein (FLAP) inhibitor, and 5-lipoxygenase deficiency on the forced swimming behavior of mice.
        Neurosci Lett. 2008; 436: 269-272
        • Brent D.A.
        • Emslie G.J.
        • Clarke G.N.
        • Asarnow J.
        • Spirito A.
        • Ritz L.
        • et al.
        Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
        Am J Psychiatry. 2009; 166: 418-426

      Reference

      1. Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, et al. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. In press 2009